Suppr超能文献

探讨白蛋白作为糖尿病足溃疡患者愈合能力生物标志物的作用:一项回顾性研究。

Examining albumin as a bioindicator of healing capability in patients with diabetic foot ulcers: a retrospective review.

机构信息

Wound Care and Hyperbaric Center, Atrium Health Wake Forest Baptist, Winston-Salem, NC.

Wake Forest University School of Medicine, Winston-Salem, NC.

出版信息

Wounds. 2023 Jun;35(6):E193-E196. doi: 10.25270/wnds/23012.

Abstract

INTRODUCTION

Identifying a bioindicator of healing capacity would be beneficial in guiding treatment of and reducing morbidity in patients with DFU. Hypoalbuminemia is a well-established risk factor for amputation and, thus, a promising candidate.

OBJECTIVE

This study was conducted to examine whether albumin values over a 12-week treatment course for DFU correlated with ulcer size and outcomes.

MATERIALS AND METHODS

A retrospective review was conducted of 793 patients who presented to the Atrium Health Wake Forest Baptist Wound Care and Hyperbaric Center between 2010 and 2022. Sixty-two patients met the inclusion criteria. Albumin values and wound size data were collected monthly over a 12-week treatment course.

RESULTS

Initial albumin values were not significantly different between patients healed by 12 weeks compared with nonhealed patients. Healed proportion and average initial ulcer size in patients with at least 1 hypoalbuminemia value (<3.0 g/dL) were not significantly different from those in patients with normal albumin levels. Patients who trended from normoalbuminemia to hypoalbuminemia displayed significantly increased wound sizes compared to patients with albumin changes within the normal range (0.04 cm² and -1.17 cm², respectively; P < .05). Monthly changes in albumin correlated poorly with wound healing (r = 0.144, P = .240), and large negative albumin trends (>0.5 g/dL per month) did not correlate with increased wound sizes compared with stable or positive trends.

CONCLUSION

Albumin's utility as a bioindicator of short-term healing capability is limited to below-normal values.

摘要

简介

如果能找到一种愈合能力的生物标志物,将有助于指导糖尿病足溃疡(DFU)患者的治疗并降低发病率。低白蛋白血症是截肢的一个明确的危险因素,因此是一个很有前途的候选标志物。

目的

本研究旨在探讨 DFU 治疗 12 周过程中的白蛋白值是否与溃疡大小和结局相关。

材料和方法

对 2010 年至 2022 年期间在 Atrium Health Wake Forest Baptist 伤口护理和高压氧中心就诊的 793 例患者进行了回顾性研究。符合纳入标准的患者有 62 例。在 12 周的治疗过程中,每月收集白蛋白值和伤口大小数据。

结果

与 12 周内愈合的患者相比,未愈合患者的初始白蛋白值无显著差异。至少有 1 次低白蛋白血症值(<3.0 g/dL)的患者的愈合比例和平均初始溃疡大小与白蛋白水平正常的患者无显著差异。从正常白蛋白血症转为低白蛋白血症的患者与白蛋白水平正常范围内变化的患者相比,伤口大小明显增加(分别为 0.04 cm² 和-1.17 cm²;P <.05)。白蛋白的月变化与伤口愈合相关性差(r = 0.144,P =.240),且大于 0.5 g/dL/月的白蛋白大幅下降趋势与伤口增大无相关性,与稳定或上升趋势相比。

结论

白蛋白作为短期愈合能力的生物标志物的效用仅限于低于正常范围的值。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验